HLS Therapeutics Inc has seen a mixed performance recently, with financial announcements influencing investor sentiment.
This week, HLS Therapeutics Inc (HLS.TO) is experiencing a slight decline in stock value, down 2.84% over the past week, closing at C$4.20. Despite this downturn, recent financial results and analyst coverage present a complex picture for investors.
Investor takeaway: Investors should consider the recent financial performance and analyst outlook when evaluating HLS Therapeutics. The company's reaffirmed guidance and growing sales in key products may offer potential for recovery, although current stock performance suggests caution.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
HLS Therapeutics Inc
HLS.TO
HLS.TO
HLS Therapeutics Inc
WealthAwesomeMarket cap
$128.54M
52W high
$5.76
52W low
$4.00
1W change
-2.84%
Beta
0.86
Analyst Price Targets
Based on analyst covering HLS
Wall Street analysts forecast HLS stock price to rise 76.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.26
+76.5% Upside
Current Price
C$4.11
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on HLS's historical volatility
30-Day Vol
29.9%
Annualized
90-Day Vol
22.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$3.44
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$3.87 | C$3.49 โ C$4.29 |
| 60 trading days | C$3.65 | C$3.15 โ C$4.22 |
| 90 trading days | C$3.44 | C$2.88 โ C$4.11 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
HLS Therapeutics Reports Q1 2026 Revenue of $12.9 Million
The reported revenue reflects a 2% year-over-year increase, supported by a 15% growth in Vascepa net sales, indicating potential for future growth despite recent stock declines.
Bull case
The company's recent revenue growth, especially in Vascepa sales, along with a positive outlook from analysts, could signal a turnaround. This makes HLS a potential candidate for long-term investment.
Bear case
However, with a negative profit margin and declining stock performance year-to-date, investors may remain cautious about HLS Therapeutics. Broader market conditions and competitive pressures add to this concern.
Recent Price Action
HLS Therapeutics Inc has experienced a minor decline this week, with its stock closing at C$4.20. Over the past month, the stock has decreased by 5.30%, and year-to-date, it is down 15.26%. Despite this downward trend, the stock's performance over the last day remains stable, reflecting no immediate volatility.
Company News and Financial Performance
No major news has been reported this week; however, recent financial results have drawn attention. HLS Therapeutics announced Q1 2026 revenue of $12.9 million, marking a 2% increase compared to the previous year, driven by a 15% growth in Vascepa net sales. The company has reaffirmed its financial guidance for 2026, projecting revenues between $56โ60 million and an Adjusted EBITDA of $18.5โ21 million. Investors may find these results encouraging, particularly as the company prepares for further product launches.
Technical Picture
From a technical perspective, HLS Therapeutics is currently trading below both its 50-day moving average (C$4.42) and 200-day moving average (C$4.72), indicating a bearish trend in the short to medium term. The stock has a beta of 0.86, suggesting it is less volatile than the market overall. The current price is approximately 11% off its 52-week range of C$4.00 to C$5.76, which may indicate a level of support around the lower end of this range. Trading volume has also been notably lower, with the latest volume at 9,200 shares compared to a 20-day average of 25,748 shares, suggesting reduced investor interest.
Advertisement
